Aveanna Healthcare Holdings Inc.

Good morning and welcome to Aviana Healthcare Holdings third quarter 2025 earnings call. Today's call is being recorded and we have allocated one hour for prepared remarks and Q&A. At this time, I'd like to turn the call over to Debbie Stewart, Aviana's chief accounting officer. Thank you. You may begin.

Good morning and welcome to Aviana's third quarter 2025 earnings call. I am Debbie Stewart, the company's chief accounting officer. With me today is Jeff Shainer, our Chief Executive Officer, and Matt Buckhalter, our Chief Financial Officer. During this call, we will make forward-looking statements. Risk factors that may impact those statements and could cause actual future results to differ materially from currently projected results are described in this morning's press release and the reports we file with the SEC. The company does not undertake any duty to update such forward-looking statements. Additionally, During today's call, we will discuss certain non-GAAP measures, which we believe can be useful in evaluating our performance. The presentation of this additional information should not be considered in isolation or as a substitute for results prepared in accordance with GAAP. A reconciliation of these measures can be found in this morning's press release, which is posted on our website, Aviana.com, and in our most recent quarterly report on Form 10-Q when filed. With that, I will turn the call over to Aviana's Chief Executive Officer, Jeff Shainer. Jeff?

Thank you, Debbie. Good morning, and thank you for joining us today. We appreciate each of you investing your time this morning to better understand our Q3 2025 results and how we are moving Aviana forward in 2025. My initial comments will briefly highlight our third quarter results, along with the steps we are taking to address the labor markets and our ongoing efforts with government and preferred payers to create additional capacity. I will then provide updates on the ThriveSkill pediatrics integration, the current regulatory environment, and year three of our strategic plan before turning the call over to Matt to provide further details into the quarter. Moving to highlights for the third quarter. Revenue for the third quarter was approximately $622 million, representing a 22.2% increase over the prior year period. Third quarter adjusted EBITDA was $80.1 million, representing a 67.5% increase over the prior year period, primarily due to the improved rate and volume environment and continued cost savings initiatives. We continue to execute our strategic transformation strategy, focusing on obtaining adequate rates from our payer and government partners for the services we provide, which is clearly evidenced in our third quarter results. As we have previously discussed, the labor environment represented the primary challenge that we needed to address to see Aviano resume the growth trajectory that we believed our company could achieve. It is important to note our industry does not have a demand problem. The demand for home and community-based care continues to be strong, with both state and federal governments and managed care organizations asking for solutions that create more capacity while reducing the total cost of care. Our Q3 results highlight that we continue to align our objectives with those of our preferred payers and government partners. By focusing our clinical capacity on our preferred payers, we achieved solid year-over-year growth in revenue and adjusted EBITDA. We also experienced improvement in our caregiver hiring and retention trends by aligning our efforts with those payers willing to engage with us on enhanced reimbursement rates and value-based agreements. While we continue to operate in a challenging environment, our preferred payer strategy supports our ability to achieve normalized growth rates in all three of our business segments. Since our second quarter earnings call, I am pleased with the continued progress we have made on several of our rate improvement initiatives with both government and payer partners, as well as continued signs of improvement in the caregiver labor market. Specifically, as it relates to our private duty services business, our government affairs strategy for 2025 is twofold. First, we are advancing our legislative agenda to improve reimbursement rates in at least 10 states. And second, we continue to advocate for Medicaid rate integrity on behalf of children with complex medical conditions. We have a strong advocacy presence with both federal and state legislatures, as well as solid support from our governors across our national footprint. State legislators have continued to recognize how meaningful private duty nursing is to the overall cost savings and improved outcomes of our nation's most vulnerable children. As it relates to private duty services rate updates, we achieved 10 rate enhancements this year, which was in line with our expectations. At this point, our private duty services legislative agenda is primarily wrapped up for this year, and we have transitioned our efforts towards similar legislative goals for 2026. Now, moving on to preferred payer initiatives. Our goal for 2025 was to increase the number of private duty services preferred payer agreements from 22 to 30. We added five additional preferred payer agreements in Q3 and are currently positioned at 30 agreements in total. Aviana's preferred payer strategy continues to gain momentum along with the Thrive SPC acquisition, which broadened our strategy into two new states, Kansas and New Mexico. Additionally, our Q3 preferred payer agreements account for approximately 56 percent of our total PDS MCO volumes, inclusive of our recent Thrive acquisition. This positive momentum in preferred payer volumes continues to highlight the shift in our caregiver capacity and recruitment efforts towards our private duty services preferred payer partners. Now, moving to our preferred payer progress in home health. Our goal for 2025 was to maintain our episodic payer mix above 70% while returning to a more normalized growth rate. I am pleased to report in Q3 Our episodic mix was 77% and our total episodic volume growth was 14.2% compared with the prior year period. The continued investments in clinical outcomes, sales resources, and a focused approach to growth is now paying dividends with Q3 total admissions of 9,700 in total or 9% growth over the prior year period. We have 45 preferred payer agreements in home health. Our dedicated focus on aligning our home health caregiver capacity with those payers willing to reimburse us on an episodic basis has led to positive year-over-year growth and improvement in our clinical and financial outcomes. Finally, as we have achieved our desired preferred payer model in private duty services and home health and hospice, We are proceeding with a similar strategy in our medical solutions business. We're in the mid-stages of implementing our preferred payer strategy in medical solutions and believe it will be fully realized by early 2026. To date, we have 18 preferred payers in medical solutions, and we expect that number to grow as we achieve our desired preferred payer model. Our gross margins have stabilized in our desired range as we align our clinical capacity with those payers that value our services and pay us in a timely fashion. I am pleased with our Q3 volume of approximately 91,000 unique patients served as we work to achieve our target operating model. While we expect our volume growth to be muted for the remainder of the year, we are experiencing improvement in our clinical outcomes, customer satisfaction, and financial outcomes. Our medical solutions business is well on its way to achieving its target operating model, and we look forward to updating you on its continued progress. We are encouraged by our rate increases, preferred pay agreements, and subsequent recruiting results. Our business has demonstrated solid signs of recovery as we achieve our rate goals previously discussed. Home and community-based care will continue to grow, and Aviana is a comprehensive platform with a diverse payer base, providing a cost-effective, high-quality alternative to higher-cost care settings. And most importantly, we provide this care in the most desirable setting, the comfort of our patients' homes. As it relates to our recent acquisition of ThriveSkill Pediatrics, I am very pleased with the integration efforts and the continued focus on superior clinical and customer experiences with our patients and families. We are on target to complete our integration by the end of this year. Our leadership team has done a nice job staying focused on our mission while achieving the expected synergies in this transaction. The Thrive acquisition is accretive to our 25 results and a great addition to our Aviana family. Now turning to the current regulatory environment with Medicaid and Medicare updates. We continue to be quite busy with our advocacy efforts. We have focused our efforts on two fronts, supporting overall Medicaid policy and defending the Medicare home health benefit for American seniors. On the Medicaid front, We continue to believe our patient population fared relatively well in the OB-BBA legislation. Pediatric and adult patients with complex medical conditions were not directly targeted in the bill, and our view is that PDM was mostly insulated in the almost $1 trillion cut to Medicaid. With that said, we are experiencing general headwinds with state Medicaid directors and governors as they plan for potentially less overall Medicaid funding, and shouldering more of their Medicaid costs in the future. As it relates to the proposed home health rule for calendar year 2026, we continue to voice our disappointment by the significance of these proposed cuts. We are aligned with the National Alliance for Care at Home and our home health peers in our strong opposition to this proposed rule. Since our last call, we've had many productive conversations with legislative leaders, both Republican and Democrat, as well as CMS leadership on the devastating impacts of the proposed home health rule. We submitted our comment letter during the CMS open comment period and have continued to advocate in all 38 Aviana states for the current administration, CMS, and Congress to halt any cuts to home health. We do expect to receive the final calendar year 2026 rule in the coming days. And although not overly material to Aviana's 2026 results, this rule is critically important to millions of seniors in America. Before I turn the call over to Matt, let me comment on our strategic plan and enhanced outlook for 2025. We will continue to focus our efforts on five primary strategic initiatives. First, enhancing partnerships with government partners and preferred payers to create additional capacity and growth. Second, identifying cost efficiencies and synergies that allow us to leverage our growth. Third, modernizing our medical solutions business to achieve our target operating model. Fourth, managing our capital structure and collecting our cash while producing positive free cash flow. And finally, engaging our leaders and employees in delivering our Aviana mission. Based on the strength of our third quarter and year-to-date results, we now anticipate 2025 revenue to be greater than $2.375 billion and adjusted EBITDA to be greater than $300 million. We believe this enhanced 2025 outlook provides a prudent view considering the challenges we still face with the evolving regulatory environment. In closing, I am incredibly proud of our Aviana team and their dedication to executing our strategic transformation while holding our mission at the core of everything we do. We offer a cost-effective, patient-preferred, and clinically sophisticated solution for our patients and families. We are the right solution for our payers, referral sources, and government partners. With that, let me turn the call over to Matt to provide further details on the quarter and our 2025 outlook. Matt.

Thank you, Jeff, and good morning. I'll first talk about our third quarter financial results and liquidity before providing additional details on our improved outlook for 2025. Starting with top line, We saw revenues rise 22.2 percent over the prior year period to $621.9 million. We achieved year-over-year revenue growth in two of our operating divisions, led by our Private Duty Services and Home Health and Hospice Division, which grew by 25.6 percent and 15.3 percent compared to the prior year quarter. Consolidated gross margin was $202.8 million or 32.6 percent. Consolidated adjusted EBITDA was $80.1 million, a 67.5 percent increase as compared to the prior year. This growth reflects an improved rate environment, increased volumes, as well as enhanced operational efficiencies. Now taking a deeper look into each of our segments. Starting with private duty services, Revenue for the quarter was approximately $514 million, a 25.6 percent increase, and was driven by approximately 11.8 million hours of care, a volume increase of 12.9 percent over the prior year. Q3 revenue per hour of $43.51 was up 12.7 percent compared to the prior year quarter, primarily driven by preferred payer volume growth and the rate enhancements previously discussed. We remain optimistic about our ability to attract caregivers and address market demands for our services when we obtain acceptable reimbursement rates. Turning to our cost of labor and gross margin metrics, we achieved $149.3 million of gross margin, or 29 percent. The cost of revenue rate of $30.89 in Q3 was up $2.27, or 8.9% from the prior year period. Our Q3 spread per hour was $12.62. We expect spread per hour to normalize as we continue to make ongoing adjustments to caregiver wages to support higher volumes and improve clinical outcomes. Moving on to our home health and hospice segment, Revenue for the quarter was approximately $62.4 million, a 15.3% increase over the prior year. Revenue was driven by 9,700 total emissions, with approximately 77% being episodic, and 12,900 total episodes of care, up 14.2% for the prior year quarter. Medicare revenue per episode was $3,215, up 3.6%, from the prior year quarter. We continue to focus on rightsizing our approach to growth in the near term by focusing on preferred payers that reimburse us on an episodic basis. This episodic focus has accelerated our margin expansion and improved our clinical outcomes. With episodic emissions well over 70 percent, we have achieved our goal of rightsizing our margin profile and enhancing our clinical offerings. We're pleased with our Q3 gross margin of 53.3%, representing our continued focus on cost initiatives to achieve our targeted margin profile. Our home health and hospice platform is dedicated to creating value through effective operational management and the delivery of exceptional patient care. Now, to our medical solutions segment results for Q3. During the quarter, we produced revenue of $45.1 million, essentially flat from the prior year period. Revenue was driven by approximately 91,000 unique patients served, and revenue per UPS of approximately $495, up 0.6% over the prior year period. Gross margin was approximately $20.3 million, or 45% for the quarter. As Jeff mentioned, we continue to implement initiatives to be more effective and efficient with our operations to achieve our targeted operating model. We are accelerating our preferred payer strategy at Medical Solutions by aligning our capacity with those payers that value our resources and appropriately reimburse us for the services we provide. We expect gross margins to normalize in the 42 to 44 percent range and UPS to accelerate its growth as we implement our targeted operating model. While I'm pleased with the integration efforts to date, we are entering the final push to complete our efficiency efforts and get back to focusing on growth and medical solutions. In summary, we continue to fight through a difficult environment while keeping our patients' care at the center of everything we do. It's clear to us that aligning caregiver capacity to those preferred payers who value our partnership is the path forward at Aviano. With the positive momentum we experienced in Q3, we remain optimistic that such trends will extend throughout 2025. We will continue to pass through wage improvements and other benefits to our caregivers in the ongoing effort to better improve volumes. Now, moving to our balance sheet and liquidity. At the end of the third quarter, we had liquidity of approximately $479 million, representing cash on hand of approximately $146 million, $106 million of availability under our securitization facility, and approximately $227 million of availability on a revolver, which was undrawn as of the end of the quarter. We had $23 million in outstanding letters of credit at the end of Q3. During the quarter, we refinanced our first lien credit facility and increased the revolving credit facility's availability from $170 million to $250 million. A combined $1.325 billion of first lien term loan was also extended and is now set to mature in 2032. These actions enhance our balance sheet strength and liquidity, allowing us to continue executing on our strategic priorities. This progress underscores our strong operating performance and the confidence our financing partners have in Aviano. On the debt service front, we had approximately $1.49 billion of variable rate debt at the end of Q3. Of this amount, $520 million is hedged with fixed rate swaps, and $880 million is subject to an interest rate cap, which limits further exposure to increases in SOFR above 3 percent. Accordingly, substantially all of our variable rate debt is hedged. Our interest rate swaps extend through June 2026, and our interest rate caps extend through February 2027. Looking at year-to-date cash flow, cash generated by operating activities was $76.1 million, and free cash flow was $86.2 million. We are encouraged by the strong cash collections and expect to generate additional free cash flow throughout the remainder of the year. Before I hand the call over to the operator, Q&A, let me take a moment to address our improved outlook for 2025. As Jeff mentioned, we now expect full-year revenue to be greater than $2.375 billion and adjusted EBITDA to be greater than $300 million. As a reminder, this year's fourth quarter includes an additional 53rd week, which will have a positive impact on both revenue and earnings. The presence of this extra week means the current fiscal year contains an additional week of business activity compared to most years. As we reflect on our Q3 results, I'd like to take a moment to express my sincere gratitude to our Aviana teammates. These strong results would not have been possible without your hard work and dedication. Looking ahead, I'm excited for the continued execution of our 2025 strategic plan and look forward to providing you with further updates at the end of Q4. With that, let me turn the call over to the operator.

Thank you. We will now be conducting a question and answer session. If you would like to ask a question, please press star 1 on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press star 2 to remove yourself from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star 2. First question. Hey, good morning, guys.

Nice quarter, and thanks for taking my question. Every year, the fourth quarter EBITDA has been higher than the third quarter. Are there any headwinds that we should be thinking about for the fourth quarter, just trying to understand the implied guidance you have for the fourth quarter after your very strong third quarter? Or is it just the standard conservatism that you've been doing for the past few years?

Good morning. Thanks for your question. And we're going to take that as a compliment. Thank you. Peter, this is our 11th quarter of beat and raise. I think as we think of Q3, we are very proud of the results. A clean quarter, a very clean quarter in Q3. Q4, with the exception of the 53rd week that Matt talked about, so a 14th week in Q4, should be very similar to Q3. We do have some seasonality that we play through at the end of the year. So, you know, the last part of the quarter has a little bit of holiday seasonality. But, no, fundamentally, we think of Q4 in the same realm as we think of the performance of business in Q3. And, again... You know, we've created a prudent – we use the word prudent. Some people call it conservative view of a beat and raise mentality. We are proud to have raised revenue at least – you know, at least $75 million and raised EBITDA of at least $30 million quarter over quarter. And if I go back to how we started the year – We started the year with a goal to achieve $200 million of EBITDA, both organically and with the addition of Thrive, which you'll hear us keep talking about Thrive. It's been a great little tuck-in acquisition for us, great business addition to our core business. We'll have raised guidance after three quarters, $100 million of EBITDA, or 50% guidance raised. We continue to be a conservative group. We love the beat and raise mentality, but, you know, raising guidance over three quarters by $100 million on a 200 basis is, in our minds, still a good day's work.

Yeah, Jeff, I'll just add to that that obviously operational performance has been amazing by the team, but also the exceptional care that the team's been delivering as well. I'll get back to it, though. There's a lot more work to do, PETA. I mean, we're going to get back to work. We're going to continue to chop wood and go do and do what we do best. we're going to continue to focus on providing not only the best patient care, but we're also going to continue to strengthen our balance sheet, leverage our organization once again, as you saw, significant leverage coming down from the beginning of the year to where we ended Q3, and we'll continue to do that in the out-quarters as well.

Great. And then, sir, a follow-up here. You've scaled up your preferred payer agreements throughout 2025, which makes for some pretty funky sequential growth this year. In the last couple of years, Freaky EBITDA has been about 26% of annual EBITDA. So is it fair to take the third quarter results and annualize that as you think about a launchpad for 2026 earnings? And even that could be conservative, I guess, with the five preferred payers you signed this quarter.

It's a fair question, Pito. You know, again, we'll start with we're staying focused on finishing the year strong. So our goals right now are to finish out 2025 and finish out strong. You know, we point people to there's a lot of momentum in the business, as you pointed out. PDS and our HHH businesses are both just heading their strides in great ways. MedSolutions, we still are working through, and I hope you've read into our comments at MedSolutions. We're doing a tremendous amount of work. We're very proud of our team, what they're doing as we speak, but want to finish that over the next kind of three to four months so they can get back to the growth algorithm that we have gotten used to. Two things I'll point out just to keep in mind. One, we had a significant amount of wage pass-through as the year has played out, and so Matt will keep bringing us back to If you look at Q2, we pointed out $9 million of timing related and wage pass-through. We had additional wage pass-through in Q3. We're still passing additional wage through in Q4. So that will continue to play through the first part of next year. And then we talked about 10 rate wins this year. It's really more than 10, but it nets down with a couple of temporary rate decreases that are in place. So we had a great year in rate wins, but we are feeling and we are hearing the general headwinds of state Medicaid systems. So We expect a similar rate story from a total number of rate wins next year, but we are working through and hearing general headwinds as the OB-BBA reality has just settled in on Medicaid systems. So we would point people towards that general headwinds as we fight through 26 Medicaid rates throughout America. That's why we love being in 29 states and continuing to grow. We love each Medicaid system is uniquely different. And I'd expect us to do more Thrive-like acquisitions in 26 to continue to build out more Medicaid states. Thanks, Peter.

Thank you. As a reminder, please limit to one question and one follow-up. Next question, Ryan Tankle with Jefferies.

Hey, good morning, guys. Congrats on the solid quarter. Maybe, Jeff, just to follow up on that comment you made to Peter. So, you know, in PDS, you've seen nice strength in hours, obviously. And as we think about the rate increases you've received year-to-date, I mean, the thing that translates into better hours, is that the right jumping-off point in terms of, like, your capacity as we think about 2026? And then maybe for Matt, as a follow-up, Historically, you've kind of spoken about a 10 to 1050 spread rate in PDS. So how should we think about the path to that level? Or is that still the right level to be thinking about considering that you've got rate increases flowing through and there's a timing dynamic?

Hey, Brian. Good morning. I think I'd pick up the Q3 PDS volume of just over 11.8 million hours of care being delivered. That obviously includes the Thrive acquisition. I would tell you that's the full impact of the Thrive acquisition in that Thrive, you know, that's 13% year-over-year growth. Thrive was about 5% of that 13%, so it still keeps our volume, you know, in line with where it was in Q2 at, you know, 6% or 7% volume growth. But I think that 11.8 million hours is the right basis to move into Q4 with. We'll have some seasonality, some normal seasonality as we move into 2026. I think, as I mentioned to Pito, a lot of our rate wins were pent-up rate wins from 24 moving into 25. We expect, as we reset our legislative goals for 2026, we'll probably still set a goal of it being double-digit rate wins. But as we've said last quarter, we'll say again, and we'll say next quarter, we expect those rate wins to be smaller in nature, you know, 2 percent, 3 percent, very specific like holiday, overtime rates, you know. So, as we work with our government partners, we do expect those, the PDS rate wins to be generally smaller than they've been over the course of the last two and a half years. The great part is we're prepared for that, we're well positioned for that. As it relates to the preferred payers and the five additional rate wins, Thrive helped that, the addition of New Mexico and Kansas as two brand new MCO states helped us in that execution. But that was the thesis of why we did the Thrive acquisition, was to roll that new markets and the current business into our relationships. And it's played out exactly as we would have expected. So I expect us to continue to execute additional preferred payer wins in Q4, and we'll reset that goal for 2026.

Yeah, and Brian, to your point on the spread itself, As expected, Q3 came right back in line with our Q1 expectations. We made sure to discuss Q2 agnosium last quarter for people to understand that that was a little bit hot. But gross margin settled in line nicely, right around 29 percent for our PDS segment. That's in line with our expectations. It's probably a little bit on the higher end of that 26 to 28 percent range that we've come to guide to in the long run here. Looking ahead, there's still additional wage pass-through to include to our caregivers, and so we'll do those wages along with some other benefits, but that will bleed into 2026 as well. So not only will that only occur in Q4, but we'll see that in Q1 and Q2 of next year too.

That makes sense. Matt, maybe my follow-up would be just on the balance sheet. So now that you've done your refi, even a base has gone up, so the leverage ratio has gone down. I mean, how should we be thinking about you know, your views on cap structure and then maybe capital deployment towards acquisitions.

Thanks. Awesome question. Yeah, really proud of our teams and what they've been able to accomplish. These great operating results and clinical results have allowed us to really focus on our cash collections as well. It takes a village to be able to do that on a continuous basis. But $86 million of free cash flow year to date, that's amazing expectations for our team and what we've been able to achieve. We'll add to that in Q4 as well, though Q3 is historically our best quarter for free cash flow generation as well. But looking ahead, we'll continue to do that. We'll bring in additional free cash flow in 2026, and we'll use that for potential M&A opportunities. But we're going to do what makes the most sense at Aviana, and whether that is deploying for M&A or paying down debt, we'll just be thoughtful on any dollars that we use.

Thanks, Brian.

Next question, Benjamin Rossi with J.P. Morgan. Please go ahead.

Hey, good morning. Thanks for taking my question here. I guess just turning to the value-based care contracting, I guess when thinking about your progress towards your broader goal of, I guess, signing 10 VBC contracts this year, could you just walk us through the market appetite you're seeing from your payer partners here? And then, have you seen any shift in how payers are maybe viewing value-based care contracts for private duty nursing going forward?

Hey, Ben, good morning. Thanks for the question. Yeah, I think the answer is just more and more and more and more. So I'll go back to the Thrive acquisition and why it made as much sense and why we'll do more Thrive-like acquisitions in PDS moving forward. And that is that our preferred payers just want more nurses and they want more of our capacity. And even we are limited on how much nursing capacity we can give them. As we talk to our now 30 preferred payers, and again, many of them are the national leading Medicaid payers in America, they just want more of what we have to offer, both in the amount of nurses, but also the relationship that we have that is tied to total cost of care through HBR programs. and fill rates. So I think as, you know, we've had conversations even this week with some of our national payers, and although it takes time to add that value-based agreement, and just as a reminder, we have bonus only, so it's only upside, so there's no, we don't take institutional risk today in any of our value-based agreements, so it's upside rewards only. Based on our ability to bend the cost curve, most of our payers are just wanting more of Aviana and more of what we have to offer, and So I can tell you from having closed the Thrive transaction, we've gotten a couple of nice feedback from our payer leaders, how impressed they were and how proud they are that we've been able to deploy more nurses to their families and their patients. So I'd expect that trend to continue as we reset our goals for 2026. But no slowdown from our MCO partners. They want more of what we have to offer.

Great. Thanks for the comments. Just as a follow-up, maybe on the home health hospice front, seeing a nice volume growth there. Episodic mix picked up nicely. For cost of revenue, it seemed like that maybe picked up a bit and was a bit of a drag on gross margin. I guess anything going on within that segment from the expense side, just with growth out there, otherwise outpaced in top line?

No, nothing crazy there, Ben, obviously. Thanks for looking at that 15.3% growth in that division is outstanding. Hospice, phenomenal growth. Episodic growth, amazing. 77% admissions are coming in as episodic as well. Those are also delivering great care afterwards. Those are funneling right into great star ratings for our teams on top of it. 53.3% gross margin. That's right in line with our expectations. 55% and change last quarter. It was a little bit hot. We kind of alluded to that one. We're continuing to invest in some training through some heartways programs with that team, but really just nothing to be concerned about. It's right in line with our expectations.

And I think Matt said it well, Ben. It's three years' worth of work. So, again, it's three years' worth of our team staying focused on the preferred payer strategy. And, again, as we think of MedSolutions, think of what you're seeing now in home health and hospice as what the future of MedSolutions will be, where we drive the majority of our volume will be aligned with our preferred payers, and that really is what drives our growth. But, no, Matt said it well. Really proud of our home health and hospice team. They've done a great job. And they've stayed focused on episodic care, which is the right payment model for that business. Thanks, Ben.

Thank you. Next question comes from Raj Kumar. Hi.

Good morning. Maybe kind of uncovering the hours growth, you know, decently strong. So just maybe trying to get in disclosures on kind of how census or patient serve trended relative to the hours per census yield. and kind of remaining opportunities as we kind of think about the spread normalizing and, you know, the company being able to hire and retain more nurses to be able to serve more volume. So maybe just trying to kind of break that out and kind of how much more room is there on the kind of hours per census side, and then what are you kind of seeing from a census opportunity perspective as well?

Yeah, I would say they're directionally in line with each other, Raj. Obviously, I would go back to the statement that everybody is always asking for more and they're needing more. And whether that is our current census that we have on there or patients that are waiting in the hospital to be discharged onto our service as well. So with the preferred payer strategy, we have been able to staff more hours and also pay our caregivers more to staff more hours and work more hours at the same time. But correlated effect, there's still high demand within our preferred payers and outside of it. there's just limited capacity with those caregivers, and there always will be, unfortunately. So as we lean into these relationships, we're going to do our best to fill as many shifts as possible on behalf of our patients and really drive that growth that you're seeing in our volume right now.

Yeah, and maybe on the home health and hospice side, just with the preferred payer strategy, maybe just kind of want to be able to compare kind of overall reimbursement on your episodic rates versus fee-for-service and kind of where that discount kind of stands or even if you're kind of at, you know, reaching parity, just maybe any information on that would be helpful as well.

Yeah, I wouldn't say we're reaching parity. So it's why we focus at almost 80%. You know, we've said 70% is our target. It wouldn't shock me if we move that to greater than 75%. You know, now that we've been, you know, four quarters in a row, I know it's a 75% episodic. It's the way of the future in this business. It is, I think our peers have figured it out. We figured it out. Episodic is the right way to think of it. It's a fair reimbursement for great clinical care and great outcomes. But I wouldn't say there's parity between non-episodic and episodic. There's not parity, and it's why we do very little of it. And it hasn't hurt us. Our referral sources understand it. Our payer partners understand it. Just like PDS, they want more nursing, more therapy care, and they want a lower total cost of care for the geriatric patients. Yeah, you'll see us stay focused on this level of care with these payers being the focus, and it wouldn't shock me if we start touching 80% of our business on a go-forward basis. We are that committed to being an episodic provider in home health. Thank you, Raj.

Thank you.

Next question, A.J. Rice with UBS. Please proceed.

Hi, everybody. First, just obviously you've mentioned made a big push and been successful in getting these preferred payers set up in the PDS business. I wonder if you have had enough time to sort of see over time how that relationship evolves. Do you get annual updates consistent with what you've been getting historically? Have you seen it evolve in any way that's worth calling out?

AJ, good morning. Thank you for the question. I think I would say, you know, we're in year four of our longest, most mature relationships, and we're in year three of a lot of the other relationships. So to your point, we're a couple years into this. I think some of the things that kind of popped out of this that maybe we didn't know going into it or didn't strategize was some of the soft things like collections and working together to help specific high-acute families get home and stay home, and just some of the other things like value-based agreement add-ons. You know, the rate is what starts this, rate and wage, so let me be specific here. The incremental rate we get, the majority that goes to wages, we've talked about now for three years to the nurses. But some of the soft stuff that then kind of adds on over time really becomes the value-based agreement, but also the collections. And we talked this year about having, you know, millions of dollars of better collections. And some of that has been calling our payer partners and having them help us with some aged accounts. And they've just been great partners on that front. So that's some of the soft stuff that's come. But I'll also say, like, they pick up the phone and just they'll call us on a tough patient that has been back to the hospital three or four times in a few months, and they'll ask us to dive in and really address that patient to help that family. And that's some of the benefits that we're able to get them. We don't ask for rate enhancements from our preparers every year, so we're thoughtful on when we go back to the well with them on needing some kind of COLA or cost of living, you know, sometimes that is every other year or every third year. So, you know, when we go back to them with those conversations, it's a productive conversation. It's a how much do we need to move nurse wages to continue to meet their needs. But I think, as we said before, out of all 30 preferred payers, whether they've been with us for four years or four months, every one of them wants more of our nurses, and that is the constant theme we hear from all of our payers. Okay.

Maybe for my follow-up, just thinking about the organic and inorganic growth in PDS as well as in adult home care, some of your peers are saying if we can just get the final rate notice done, that could open the floodgates, give us more clarity on deals and where to look for expansion opportunities. Others are saying that's not enough. We need more clarity on the long term. reimbursement profile on the PDS side, you're saying you're seeing a little caution in some states. I guess I'm just wondering, is there anywhere where you're thinking about leaning in more to new opportunities, growth, either organic development or acquisitions or where you're being a little more cautious?

I'll go back to who we are to start with. Almost 80% of our company is generated from our PDS segment, so that is the underpinning of Aviana, always has been and certainly is. We added two new states with Thrive, so we're now in 29 Medicaid states. I think Matt and I would tell you we'd like to be in about 38, maybe 40 total Medicaid states. There's a couple of key states that our large national Medicaid partners are in that we're not, you know, like Ohio, West Virginia, Kentucky, those states. We don't have any Medicaid presence there today. So over time, we'd like to fill those states in. But we want to continue to expand our Medicaid reach, both pediatric and adult. We're a skilled focus company, as you know, AJ. So we always lead with skilled services, nursing services. That is our focus. And then I guess, Matt, pivoting back to home health, You know, we're in a good position that only today about 10% of our revenue is in home health and hospice. We're big believers in home health. We believe home health is the right solution for America's seniors, and we'd like to see a nice rule settled here. But, Matt, how do you think about deployment?

Yeah, no, I just would go back to that. We're always going to continue to advocate on behalf of our patients and our families, regardless of the industry, regardless of the division. We're going to continue to do what we do best. We're going to deliver that exceptional patient care that people know us for, We're going to do that most cost-efficient setting in that patient's home. And then regardless of any policy changes out there, AJ, we're going to focus on that quality care, operational efficiencies, and those close partnerships with our payers. We think that by maintaining those really high standards and demonstrating really good clinical outcomes, everything will work out in the long run here. I think we're well-positioned with our size, scale, and density in technology and our clinical outcomes that these partnerships will continue to grow. and that we'll be on the right side of healthcare, that we will be a cost savings to the healthcare system. Thank you, AJ.

Okay. Thanks a lot.

Andrew Mock with Barclays. Please go ahead.

Hi. Good morning. Just to follow up on the hours growth, can you spike out the contribution of Thrive in the quarter and how volumes performed on a same-store basis? Because it still looks like a pretty meaningful thing. increase year over year? And once Thrive is fully integrated, what's the annualized earnings contribution expected in that? Thanks.

Yeah, Andrew. With Thrive Business, first off, it's a really great business. The team has done a really nice job integrating it into the Aviano organization. Q3, to your point, reflects that full financial impact of Thrive. It was in there for a very full quarter on there. If you go back and look at our Q2 on an hours basis, we were mid to high single digits out there. That's exactly organically what Aviana was doing as well in Q3. The increments of what you're seeing is from Thrive. What we talked about previously, Thrive is coming in at roughly $100 million of revenue and about 7.5 times multiple from the purchase price post synergies itself. We're going to be just a little bit north about that, but the team has done a phenomenal job getting after synergies, integrating the organization, and really bringing in to be part of Aviano.

And I think Matt has said that well. We guide people over three to five years that PDS should be in that kind of 4% to 5% organic growth rate. We've been a couple of points north of that now for three quarters plus. Q3 represented that organically. We were in that same kind of six, six and a half, seven percent organic and then the nice addition of Thrive and Again, I think as we came out of Q2, we guided people to think of Q2 as $79 million versus $88 because of the $9 million of timing. And then we said there's a couple million dollars or more of wage pass-through. So we thought that the organic business would land kind of in the mid to high 70s, which is where it did. And then, as Matt talked about, the addition of Thrive comfortably settled us right at that $80 million amount. And that's the full impact. We're wrapping up integration literally in the month of November. And We'll have some AR runoff into early, mid, next year, as normal as the systems run off, but we're really putting the integration to bed here in the month of November and excited to go do it again.

Great. I wanted to follow up on some of the comments around the uncertainty around state budgets and the indirect impact that might have on reimbursement. Are those comments more directional in nature, or are there specific actions that states are taking that are driving that more prudent posture? Thanks.

It's more directional in nature, but, you know, we've spent the entire year talking to both governors, state Medicaid budget directors, you know, and the key majority leaders in, you know, almost 30 states. And it's been the same similar conversation in all 29 states, which is a little bit of uncertainty, a little bit of let's see how this shakes out, a little bit of we want to see how the OBBA settles in. So, you know, I think at this point most states have kind of figured out what it means to them. Some, Wisconsin was a big winner this year. Wisconsin had a major increase to their Medicaid PDN rate. But we had a couple of states who temporarily put in 2%, 3% reductions just so they could balance their 2026 budget. So we've seen a little bit of everything in the process, but I think as we think of 26 and 27, we think that generally in nature there's going to be some headwinds the states have to work through.

Yeah, I think the diversity of the 29 states for PDN

nice position for some states win, some states hold, some states are going to just be out there for a little bit, but that diversification is a positive for Aviano.

Thank you, Andrew.

Hey, operator, we're here.

Yes.

Peanut, no.

Hey, John. Sorry, we didn't hear that question. So you guys went on mute for a minute. So just going back to your payer relationships, You said you offer to bend the cost curve in a snub-side-only deal. What does that mean exactly? And my follow-up is, does having a payer deal in pediatrics grease the skills for a payer deal in home health and hospice and med solutions? Thanks.

That's great. Let me start with the second one, because the second one is easier than the first one. And I'll use United, or if you just think about United. Our answer would be no. It's two totally separate sections of the payer itself. You know, United Community, which is our Medicaid business, is totally different than the United Medicare Advantage. We talk to both sides of United in this example, but the paths never really cross inside of their shop. So in most of our payer partners, talking to a Medicaid pediatric, you know, rate person is – has very little benefit to the Medicare geriatric rate, you know, peer to peer. Many times they don't even know who the peer is in nature. So, unfortunately, unfortunately, it doesn't bleed over. But going back to your first question about our payer contracts. So, first of all, each of our nine, I think, nine to date value-based agreements are in addition to an enhanced rate. So, all 30 of our preferred payers have an enhanced rate, which means an enhanced wage for the nurse in those cases. All nine of the value-based agreements are different in nature. Even some of those with the same payer, they're different. But most of them focus on really two fundamental things. One is fill rate, the amount of hours that we've been authorized to fill. And the goal is that we fill as many of those hours as possible. The payer wants us to fill 100%. Most of our targets are between 80% and 90%. Where our goals are is to land between 80% and 90% fill rate. And then the second part is really HBR or MLR, however they think of it, is some form of a target cost for the actual services that we provide, and really tying to acute care spend, right? So reducing the acute care spend. Most of our nine contracts have something to do with the two of them. There may be a third and fourth, like customer satisfaction, you know, and other feedback from customers, but most of them are driven by HBR percentage and a fill rate target.

And it just to ask the obvious question. So the fact that you're, you just have more nurses, you have more, you know, athletes on the field, you can one phone call from them. They can get more spots filled and calling five of your smaller competitors. Is it, is it, I know it's probably not that simple, but is that a big piece of it?

I would think it's scale. They want scale. They want scale of nurses, but also scale of geography. They want technology. They want our clinical outcomes. They want the best. But yes, they want more nurses. And most of these payers, if you think of their geography, they're in a state like Texas. They're in both Dallas, but they're also maybe in South Texas. So it's urban and very rural. And they want both. They want you to cover both of those with equal tenacity. But yes, they... They want our alignment of our nurses and our scale with their scale of their beneficiaries. But yes, that is, you've nailed it. Okay, thank you. Thanks, John.

Next question, Ben Hendricks, RBC Capital Markets. Please go ahead.

Hi, this is Michael Murray on for Ben. Thanks for taking my question. We're getting a lot of questions on the sustainability of growth of the preferred payer relationships. Could you give us an idea of the room to run here? You targeted 30 in 2025. Any idea what the goal would be for 2026? And then what is the potential to increase the number of patients you take within a preferred payer relationship?

Hey, Michael. Good morning. I guess I'll start with some people ask us, you know, what inning are you in in a preferred payer strategy? And Clearly, we're past the first inning, but we're way before the ninth inning. I'll put it that way. We're somewhere in the middle of the story. You know, we've added volume metrics in PDS. Our goal would be at some point in the future to add a volume metric and med solutions tied to the number of preferred payer accounts. If you think of our PDS volumes today, you know, we announced this quarter 56% of our MCO volumes are aligned with a preferred payer. I think that would tell you, you know, we're a little bit more than halfway there. We've said before, we don't think that we'll get to 100% of the MCO volumes being with a preferred payer, but we should get to the low to mid-80s and maybe one day the high 80s in percentages over the next couple of years. I think as we reset our goals, we met as a team a few weeks ago and started planning for 26. We're in our budgets as we speak now. As we reset our goals for 26, clearly 30 is no longer the goal. We'll be somewhere in the mid to high 30s, maybe even approaching 40, but But it's also the value in why we're looking for additional markets. I mean, Thrive is a great example. I mean, we added two brand-new states. We picked up a couple of preferred payers in those states right out of the gate, enhanced relationships. So I tell you, there's still a long, long runway in front of us. And, again, what we're doing in MedSolutions is exactly the same as what we've done in Proprietary Services and Home Health and Hospice, which is define the preferred payers, define the target operating model, and then align our capacity with those payers. And that's what you'll hear us talk about in 26 for MedSolutions.

All right. Thank you. And then I had a follow-up question on capital structure. I wanted to see what your intermediate leverage targets were, and do you anticipate hitting those through EBITDA growth, or would you use cash flow to pay down debt? Thanks.

Great question, Michael. And obviously, once again, really impressed with the team being not only a free cash flow generating organization, but a meaningful free cash flow generating organization. $146 million cash on hand in the quarter. That's phenomenal work from the team through a cash collections and operations efforts. We're currently sitting at, what, 4.62 times net leverage currently. I mean, we're down almost three turns of leverage this year. We were 2.77 turns last year. We've got line of sight to continue deleveraging the organization and the out-quarters as well. We have an internal goal to make sure we have a three-handle in front of that. I mean, that's something we're going to be at. We probably won't be there wrapping up this year, but into 26 and into 27 to have a three-handle in front of that. We'll be thoughtful with our dry powder. It's always nice to have dry powder sitting out there for some potential deals that might come through. But if it makes the most sense to the organization, we're not afraid of paying down debt at the same time. So I think thoughtfulness is what you should take away from this one. But right now, we're going to sit on that and see if any opportunities arise. Thanks, Michael.

Next question, David McDonald with Truist Securities. Please go ahead.

Good morning. Thank you. Guys, just one left. I'm just kind of curious, wanted to piggyback on AJ's question from earlier. Just with regards to home health and some of the uncertainty there, I'm just curious, has that impacted the strength of the pipeline of opportunities there for you guys? And what would you kind of need to see in terms of the final rule to get comfortable starting to potentially more meaningfully deploy capital there, just given some of the reimbursement uncertainty?

Yeah, it's a great question, David. And we've had a lot of, there's been a lot of activity the last six months, you know, small, medium-sized activity in both Medicaid and Medicare, both home health and hospice on the Medicare side from an M&A standpoint. And we've looked at a bunch of little or tuck-in type opportunities on both Medicaid and Medicare. We've not been in a position today where we've been ready to pull the trigger on a home health or hospice asset. pending the final rule. Our expectations are that the rule would be somewhere close to neutral, to zero. That's probably a little bit of aggressive expectation, but that is the ask that we have on hand, as you know, from the industry at large, is basically a multi-year pause and no cuts. We will leverage the 78% of the business to grow the 10% of the business. We've said that before, and we mean it. So we'll leverage our Medicaid book to grow on the Medicare side. You know, we're really not a hospice buyer at mid-teens multiples, right? So we're more disciplined as a buyer. We like to buy where we can buy in the, you know, high single digits, low double digits, and have a clear path to mid-single digits post-energy. So... We'd like to see something that is close to zero or effectively zero. By the way, we expect to see that next week. So our intel says that that probably is coming out, you know, late next week or certainly the following week. So we will know soon enough. And I think for all of us, as you know, David, it's just getting certainty. Just give us a certain answer that we can read into the future with this administration, and then we're ready to go to work. Okay. Thanks very much. Thanks, David.

I would like to turn the floor over to Jeff for closing remarks.

Thank you, Stacey, and thank you so much for your interest in our Aviana story. We look forward to updating you on our continued progress right after the first of the year. Thank you, and have a great day.